Get the Stockscreener App
2.57
15.77%
0.35
After Hours:
2.51
-0.06
-2.33%
Tuhura Biosciences Inc stock is traded at $2.57, with a volume of 1.08M.
It is up +15.77% in the last 24 hours and up +0.78% over the past month.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
See More
Previous Close:
$2.22
Open:
$2.28
24h Volume:
1.08M
Relative Volume:
1.28
Market Cap:
$163.66M
Revenue:
-
Net Income/Loss:
$-30.92M
P/E Ratio:
-4.2627
EPS:
-0.6029
Net Cash Flow:
$-27.39M
1W Performance:
+17.35%
1M Performance:
+0.78%
6M Performance:
+189.81%
1Y Performance:
-4.81%
1-Day Range:
$2.255
$2.5795
1-Week Range:
$2.15
$2.5795
52-Week Range:
$0.41
$3.90
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.57 | 141.38M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq: Corporate Information, Address, and Key Details - Minichart
TuHURA Biosciences Inc (HURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TuHURA Sets 2026 Virtual Annual Meeting, Proposal Deadlines - TipRanks
Shareholder deadlines set for TuHURA (NASDAQ: HURA) 2026 meeting - Stock Titan
TuHURA Biosciences Inc (HURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TuHURA Biosciences Inc (HURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TuHURA Biosciences Inc (HURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TuHURA Biosciences Inc (HURA) Institutional Confidence - TradingKey
Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com - Investing.com Canada
HURA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEstimate Revision Count - newsline.com
TuHURA Biosciences (HURA) Rallies 2.8% as Biotech Stock Tests Key Resistance Near $2.50Inside Day Breakout - newsline.com
TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025 - grafa.com
TuHURA files IND for TBS-2025 in blood cancer study - Investing.com
TuHURA files IND for TBS-2025 in blood cancer study By Investing.com - Investing.com Nigeria
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - PR Newswire
TuHURA Biosciences Inc (HURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates, Stock Rises Despite Wider Loss - newsline.com
HURA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Stage; Stock Gains 5.29%Margin Expansion Trends - newsline.com
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Miss Highlights Pre-Revenue Biotech's Expense Management ChallengesSurprise Factor Analysis - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseMargin Improvement Report - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates, Stock Slides on Higher Cash Burn and Pre-Revenue StatusRevenue Miss Report - newsline.com
HURA News | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq Listing Details and Company Information - Minichart
TuHURA Biosciences Draws on New $50M Credit Facility - TipRanks
TuHURA (NASDAQ: HURA) taps $1.7M from $50M revolving loan facility - Stock Titan
TuHURA Biosciences (HURA) CEO James Bianco gifts 150,000 shares to adult sons - Stock Titan
HURA: Refining TBS-2025 Development Plan - Yahoo Finance
TuHURA Biosciences Inc. (HURA) Rises 6.84% as Price Tests Key Resistance LevelTriangle Correction - newsline.com
TuHURA Biosciences Inc. Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineGuidance vs Actual - newsline.com
TuHURA Biosciences (HURA) Gains Nearly 7% as Shares Approach Key Resistance at $2.62Synthetic Short - Newser
Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks - The Globe and Mail
TuHURA Biosciences Secures $50M Credit Facility and Reports Q1 2026 Financial Results, Advancing Phase 3 Immuno-Oncology Programs - Minichart
TuHURA Biosciences Extends Cash Runway and Advances Pipeline - TipRanks
TuHURA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary - TradingView
TuHURA Biosciences (HURA) adds $50M credit line amid $7.5M loss - Stock Titan
TuHURA Biosciences (Nasdaq: HURA) secures $50M credit facility and outlines Q1 2026 pipeline milestones - Stock Titan
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences, Inc. (HURA) Eps Diluted (TTM) - Zacks Investment Research
HURA Stock Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - ChartMill
TradingKey - TradingKey
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Number of shareholders of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Why TuHURA Biosciences (HURA) is trading below its true worth (Trend Weakens) 2026-05-08Beta Neutral Pair - newsline.com
Tuhura Biosciences, Inc. 2025 Annual Report: Financial Results, Research & Development Expenses, and Key Business Highlights - Minichart
HURA Should I Buy - Intellectia AI
TuHURA Biosciences (NASDAQ: HURA) updates Kineta merger pro forma loss to $34.6M - Stock Titan
TuHURA Biosciences (NASDAQ: HURA) details 2025 loss and cash runway - Stock Titan
Tuhura Biosciences Inc Stock (HURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):